428 Pharma is a Netherlands-based pharma company pioneering the development of the world’s first Long-Acting Injection (LAI) for the treatment of Major Depressive Disorder (MDD). Our approach leverages the FDA’s 505(b)(2) regulatory pathway to accelerate development timelines, reduce costs, and bring innovative mental health therapies to patients faster. With patents granted until at least 2043 and a potential to reach $4B in peak sales, our lead program has the potential to transform the standard of care in depression treatment.